Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Zepzelca
Lurbinectedin is an antineoplastic agent indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. It is a synthetic analogue of trabectedin, a natural product derived from the marine tunicate Ecteinascidia turbinata. Lurbinectedin acts by binding to the minor groove of DNA, bending DNA structure and affecting several transcription factors, ultimately leading to cell cycle arrest and apoptosis (programmed cell death).
Lurbinectedin is used to treat metastatic small cell lung cancer in adults who have experienced disease progression on or after platinum-based chemotherapy.
Lurbinectedin can cause myelosuppression, including neutropenia, thrombocytopenia, and anemia. Patients should have complete blood counts monitored frequently. Lurbinectedin can also cause serious liver injury, including acute hepatitis and hepatic failure, and patients should have liver function tests monitored regularly.
Outcome:
Increased lurbinectedin exposure
Mechanism:
Inhibition of lurbinectedin metabolism
Outcome:
Increased lurbinectedin exposure
Mechanism:
Inhibition of lurbinectedin metabolism
Outcome:
Decreased lurbinectedin absorption
Mechanism:
Changes in gastric pH
Most likely new formulation: Liposomal lurbinectedin for improved delivery and reduced toxicity (2025, 60% confidence).
Based on current clinical trial data and approval status, there is a high likelihood of lurbinectedin remaining a key treatment option for relapsed SCLC in the near future (80% confidence).
Antineoplastic Agent, Alkylating agent
Tetrahydroisoquinoline alkaloid